We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
重组人生长激素治疗儿童特发性矮小症的疗效 及对血清Ghrelin和IGF-1 水平的影响.
- Authors
郝利苹; 刘戈力; 杨箐岩; 郑荣秀; 武明雷; 姜丽红; 魏莹; 鲍鹏丽
- Abstract
Objective: To investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with idiopathic short stature (ISS) and the effects of serum Ghrelin (Ghrelin), insulin-like growth factor -1 (IGF-1) levels. Methods: 114 children with ISS who were treated in our hospital fromJanuary 2014 to October 2016 were selected as the research objects. The patients were divided into two groups according to the random number table: the experimental group (n=57) and the control group (n=57). The control group was given conventional treatment, and the experimental group was treated with rhGH on the basis of the control group. The clinical efficacy of the two groups after treatment was compared, the levels of serum Ghrelin and IGF-1 were observed and compared between the two groups before and after treatment. Results: The height and growth rate of the two groups after treatment were higher than before treatment, and the experimental group was higher than that of the control group, the differences were statistically significant (P< 0.05). There were no significant differences in weight, total thyroxine, bone age and fasting blood glucose level between the two groups after treatment (P>0.05). The level of Ghrelin in two groups after treatment was lower than that before treatment, and the experimental group was lower than that of the control group, the level of IGF-1 in two groups after treatment was higher than before treatment, and the experimental group was higher than that of the control group, the differences were statistically significant (P<0.05). The incidence of adverse reactions in the experimental group was 5.26%, while that of the control group was 0.00%, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:The treatment of rhGH in children with ISS is satisfactory, can significantly improve the serum IGF-1 and Ghrelin levels in children with ISS, safety and no side effects, and promote the healthy growth of children.
- Subjects
SOMATOMEDIN; HUMAN growth hormone; SHORT stature; BLOOD sugar; GHRELIN
- Publication
Progress in Modern Biomedicine, 2018, Vol 18, Issue 20, p3854
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2018.20.011